Department of Dermatology, Venereology and Allergology, Charité Universitätsmedizin Berlin, Germany IMS Health GmbH & Co. OHG, Frankfurt, Germany.
J Dtsch Dermatol Ges. 2012 Mar;10(3):180-4. doi: 10.1111/j.1610-0387.2011.07787.x. Epub 2011 Sep 17.
Chronic hand eczema (CHE) is a common dermatological disease. Due to different etiologies, severity levels, and high therapy costs, it presents a challenge for dermatologists. Nowadays, it is recommended that treatment be adapted to the severity of the disease. According to the guidelines on the management of hand eczema, topical corticosteroids are the first-line therapy for hand eczema.
The present study investigated the prescription profile of topical treatments. Data sets from 13 191 patients with hand eczema were analyzed.
The results indicate that topical corticosteroids are frequently prescribed for the treatment of hand eczema. Corticosteroid treatment (72.6 %) was most commonly prescribed by private practice physicians. Betamethasone was the most frequently prescribed, but other substances such as mometasone furoate, prednicarbate, clobetasol, and methylprednisolone aceponate were often prescribed as well.
The results show that the concept of the risk-to-benefit ratio is reflected by the prescription profile of topical corticosteroids (therapeutic index). However, even corticosteroids with a less favorable therapeutic index are sometimes prescribed, perhaps due to economic reasons.
慢性手部湿疹(CHE)是一种常见的皮肤病。由于病因不同、严重程度不同、治疗费用高,给皮肤科医生带来了挑战。如今,建议根据疾病的严重程度进行治疗。根据手部湿疹管理指南,局部皮质类固醇是手部湿疹的一线治疗药物。
本研究调查了局部治疗的处方情况。分析了 13191 例手部湿疹患者的数据集。
结果表明,局部皮质类固醇常用于治疗手部湿疹。皮质类固醇治疗(72.6%)最常由私人执业医生开具。倍他米松是最常开的处方,但也经常开莫米松糠酸酯、泼尼卡酯、卤倍他索和醋酸甲基泼尼松龙等其他物质。
结果表明,局部皮质类固醇的处方情况(治疗指数)反映了风险效益比的概念。然而,即使是治疗指数较差的皮质类固醇有时也会被开处方,这可能是由于经济原因。